Pyrimidine compounds
US5688798A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Sep 11, 1996 |
| Grant date | Nov 18, 1997 |
| Priority date | — |
| Expiry date | Sep 11, 2016 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D401/06
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Compounds of the formula ##STR1## wherein R.sup.1 and R.sup.2 each individually are lower-alkyl or amino, PA1 A is ##STR2## B is hydrogen in A.sup.4, A.sup.5 and A.sup.6 ; ##STR3## in A.sup.1 -A.sup.6 ; lower-alkoxy in A.sup.4 -A.sup.6 ; PA2 and lower-alkyl, styryl, phenylethynyl or benzoyloxy-lower-alkyl in A.sup.1 and A.sup.2 ; PA1 n is 0, 1 or 2; PA1 m, p are, independently 0, 1 and PA1 R.sup.3, R.sup.4, R.sup.5 and R.sup.6 each independently are hydrogen, halogen, lower-alkyl, trifluoromethyl, lower-alkoxy or nitro, and pharmaceutically acceptable acid addition salts thereof. These compounds are useful in the control or prevention of illnesses which are caused by disorders of the dopamine system, in particular psychotic illnesses such as schizophrenia.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.